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Abstract
Purpose:  To report a case of recurrent nummular keratitis in a pediatric patient with
Hyperimmunoglobulinemia D syndrome.
Methods: A retrospective chart review.
Results: A 14-year-old boy with Hyperimmunoglobulinemia D syndrome (HIDS) presented with
photophobia and ocular irritation concomitant with disease exacerbation. He was found on exam
to have significant nummular keratitis, which responded to a short course of topical steroids.
Despite acute response to local immunosuppression, the patient had several recurrent attacks and
eventually developed a large corneal scar and decreased vision. After initiation of infliximab therapy
his ocular sequelae improved dramatically and his vision returned to 20/20.
Conclusion: One possible form of end-organ damage associated with HIDS is vision threatening
nummular keratopathy.
Background
Hyperimmunoglobulinemia D syndrome (HIDS) results
from mutations in the mevalonate kinase (MVK) gene
resulting in deficiency of MVK, an important enzyme for
cholesterol biosynthesis. Patients with this rare condition
characteristically experience recurrent episodes of fever
and inflammation.[1] Starting in the first year of life,
patients have periodic fever episodes with accompanying
lymphadenopathy, gastrointestinal complaints, aphthous
ulcers, arthralgias, and skin reactions. These attacks typi-
cally last 4–6 days and recur every 4–6 weeks. We report
herein a case of HIDS with photophobia secondary to sig-
nificant nummular keratitis that resulted in decreased
vision and corneal scarring.
A mutation in the MVK gene can affect enzymatic activity
of MVK and results in one of two distinct syndromes,
HIDS or mevalonic aciduria. In patients with HIDS, the
activity of MVK is reduced to 5–15% of normal. The
resulting clinical picture may include any or all of the
aforementioned symptoms. Laboratory analysis reveals a
vigorous acute-phase response during attacks; including
elevated erythrocyte sedimentation rate, C-reactive pro-
tein and leukocytosis. Most patients have increased serum
immunoglobulin (Ig) D and A levels. Mevalonic aciduria,
an autosomal recessive disorder with complete absence of
MVK activity, usually presents with a more severe clinical
picture. It is characterized by periodic attacks of fever and
inflammation, along with developmental delay, ataxia,
and dysmorphic features. Ocular symptoms consist of ret-
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inal dystrophy, moderate optic atrophy and nuclear cata-
racts.[2] However, specific ocular surface inflammation
has not been described previously in either condition
associated with MVK mutations, and there are no reports
of ocular sequelae of HIDS.
MVK is essential for isoprenoid metabolism, which has
end products such as cholesterol, ubiquinone and doli-
chol, as well as a role in isoprenylation of proteins.[3]
How a deficiency of mevalonate kinase leads to inflam-
mation is incompletely understood. The clinical picture of
HIDS is believed to reflect enhanced proinflammatory
cytokine production by mononuclear cells.[4] A defect in
apoptosis of lymphocytes has also been detected.[5] The
proinflammatory state, with resultant overproduction of
tumor necrosis factor alpha (TNF-α) and interleukin 1-
beta (IL1β), is believed to induce the disease's characteris-
tic attacks.[3]
Report of case
A 14-year-old white boy presented to the St. Louis Chil-
dren's Hospital Emergency Department with primary
complaints of fever, arthritis, and flu-like symptoms of
one week's duration. He had been diagnosed 3 years prior
with HIDS after a long history of similar presentations.
Laboratory examination at this visit revealed IgD levels to
be 265 IU/ml (upper limit of normal <100 IU/mL).
Genetic testing subsequently established he was a com-
pound heterozygote for two common mutations in the
MVK gene, V377I in exon 10 and I268T in exon 8
(GeneDx, Inc, Gaithersburg, MD). At the time of our ini-
tial encounter, he was being followed by a rheumatolo-
gist. His flares were managed with ibuprofen as needed.
His ocular history was significant for multiple episodes of
"eye inflammation" that occurred in conjunction with his
febrile attacks. In the past, he had been told he likely had
conjunctivitis secondary to viral illness; however he had
not been evaluated by an ophthalmologist. During this
presentation we were consulted for his new complaint of
photophobia and ocular irritation. At our initial exam,
visual acuity was 20/50 in the right eye and 20/40 in the
left. Both eyes had conjunctival injection on external
examination. Slit-lamp exam revealed multiple punctate
anterior corneal stromal opacities with active peripheral
corneal stromal keratopathy consistent with sterile
inflammatory nummular keratitis. We prescribed topical
prednisolone acetate and cyclopentol 1% to treat the
inflammation and photophobia.
At follow-up one week later, our patient exhibited a
robust response to topical corticosteroids. Both his photo-
sensitivity and nummular keratitis had improved,
although his visual acuity remained unchanged. Over the
subsequent year, our patient had multiple, similar presen-
tations to our office. His exam routinely consisted of pho-
tophobia, conjunctival injection and nummular keratitis
which occurred in conjunction with arthritis and fever.
His ocular inflammatory symptoms resolved quickly with
topical prednisolone acetate and cyclopentol 1%.
Despite a satisfactory inflammatory response to topical
corticosteroid, with each successive flair-up of disease our
patient had progressive corneal scarring and worsening of
his vision. Approximately 1 year after our initial encoun-
ter, the decision was made to begin treatment with simv-
astatin (10 mg/day). We saw him once while on this
treatment regimen; he was still experiencing disease flairs,
elevated laboratory values (ESR = 39 mm/h, CRP = 20.5
mg/L), and ocular complaints. He noted photophobia,
intermittent pain and redness and decreased visual acuity.
Despite this regimen, he eventually developed a large cen-
tral corneal scar in the right eye located in the region of
recurrent keratopathy. Visual acuity in this eye conse-
quently decreased to 20/80. At this point, his rheumatol-
ogists began infliximab infusions (7.8 mg/kg for a total of
600 mg) every 8 weeks. Due to concern that his severe
arthritis may lead to permanent joint damage, weekly
methotrexate (20 mg) was also a part of his regimen.
After eight cycles of therapy, his ocular exam was remark-
ably improved. He no longer complained of photopho-
bia. On exam, both eyes had clear conjunctiva, the central
corneal opacities had resolved, and despite residual cor-
neal scarring, his uncorrected visual acuity had returned to
20/20 in both eyes [see Additional file 1, 2]. He no longer
needed artificial tears and reported no ocular complaints
since initiation of infliximab 12 months prior.
Discussion
To date, our review of the literature revealed no reported
cases of conjunctivitis or keratitis associated with HIDS.
However, ocular surface manifestations of HIDS may be
underreported. At the referral center that maintains the
world's largest database of patients with HIDS based in
Nijmegen, the Netherlands, many HIDS patients have
mild conjunctivitis during attacks. These patients were not
evaluated by ophthalmologists and therefore, it is possi-
ble that their complaints may reflect undiagnosed ocular
inflammation attributable to HIDS (Dr. Anna Simon, per-
sonal communication).
Over the course of three years, our patient repeatedly pre-
sented with complaints of "red eyes" and photophobia.
His ocular irritation was initially attributed to viral con-
junctivitis. By the time the patient was seen in our clinic,
he already demonstrated corneal scarring and secondary
vision loss. Throughout his history, our patient continued
to show signs of corneal inflammation despite treatment
with ibuprofen, steroids and simvastatin. While his kera-
titis responded to topical corticosteroids, his vision neverPediatric Rheumatology 2009, 7:14 http://www.ped-rheum.com/content/7/1/14
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fully improved. It was not until initiation of infliximab
therapy that his vision improved to 20/20. The complete
resolution of his keratopathy with an anti-TNF-α agent
suggests the drug works not only to reduce the frequency
of HIDS flares, but also to decrease inflammatory media-
tors that cause damage occurring between attacks.
There currently is no standardized treatment regimen for
HIDS. Traditional anti-inflammatory drugs (e.g. steroids)
have moderate effects on tempering attacks. Given the
role of mevalonate kinase in cholesterol biosynthesis,
inhibition of HMG-CoA reductase with statins has been
theorized to reduce the frequency of inflammatory
attacks. One study did show simvastatin effectively low-
ered the duration of illness by reducing the frequency of
febrile attacks, but its ability to prevent end-organ damage
(arthritis, skin lesions, hepatospenomegaly, etc.) has been
less satisfactory.[6] In fact, in our case we saw no improve-
ment in our patient's ocular symptoms on simvastatin
therapy. Interleukin-1 (IL-1) receptor antagonists (e.g.
anakinra) have been used with reported success in vac-
cine-induced models of HIDS. They are thought to limit T-
cell mediated immunity and cytokine production, espe-
cially during attacks. [7] Isoprene deficiency also leads to
an excessive amount of proinflammatory cytokines and a
downstream increase in plasma levels of TNF-α. There-
fore, anti-TNF-α agents are being used in patients who
continue to demonstrate end-organ damage despite treat-
ment with other agents.[8] Results are mixed, but include
a decrease in acute-phase response, improvement in clin-
ical symptoms, and cessation of febrile attacks.[9,10]
Given the chronicity of the keratitis and associated cor-
neal scarring with visual loss observed in our patient, we
recommend that patients with HIDS and non-specific
ocular complaints be evaluated and managed by an oph-
thalmologist. Furthermore, because of the recurrent
nature of the keratopathy, good response to topical ther-
apy, and the potential for visual loss, we recommend judi-
cious use of topical corticosteroids to suppress the ocular
surface inflammation in patients with HIDS. In cases such
as ours, where vision loss was persistent despite good
acute response to topical corticosteroids, we suggest con-
sideration of systemic biologic therapy. Because the TNF-
α antagonist specifically counteracts the increased acute-
phase response seen in HIDS, it may be better suited than
simvastatin or ibuprofen when end-organ damage, such
as corneal scarring, is apparent.
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Additional file 1
Close-up corneal photograph taken after resolution of keratopathy fol-
lowing treatment with infliximab. Note residual stromal opacities at the 
3 o'clock position.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1546-
0096-7-14-S1.jpeg]
Additional file 2
Zoomed out view of resolved keratopathy. Unimpressive picture of a 
residual iron line, all that remains of what was a rather inflammed cor-
nea.
Click here for file
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